-

Nucleus RadioPharma Appoints Former McKesson, Novo Nordisk Executive Kathy Spencer-Pike as Chief Commercial Officer to Drive Business Growth

Kathy Spencer-Pike brings more than two decades of experience within highly matrixed Fortune 50 environments as well as fast-paced growth and start-up enterprises

ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer. As a seasoned veteran with decades of commercial experience at McKesson, Novo Nordisk, Sanofi and Pfizer, Ms. Spencer-Pike will be responsible for accelerating the growth of the startup following its oversubscribed $56M Series A in October. Ms. Spencer-Pike follows a string of C-Suite appointments including Geoff Johnson, M.D., Ph.D. as Chief Scientific Officer, Kevin Haehl as Chief Development Officer and Mark Przekop as Chief Operating Officer.

“Kathy’s sterling track record of enhancing organizational value, paired with her expertise in creating, developing, and leading high-achieving teams in new business, client success, and business expansion is the perfect addition to round out our C-Suite,” said Charles S. Conroy, CEO of Nucleus RadioPharma. “On the heels of our successful funding round to increase the radiopharmaceutical accessibility, we are eager to lean on Kathy’s experience and insight to accelerate further growth and advance our commitment to delivering life-saving treatments to patients with cancer.”

Before Nucleus, Ms. Spencer-Pike was Chief Sales Officer at McKesson where she spurred significant company growth, built a high-performance commercial team and merged three legacy organizations into a single commercial organization achieving unprecedented double-digit growth year over year. Ms. Spencer-Pike previously was VP, Commercial Leader for Novo Nordisk, successfully leading the planning, development and execution of market and sales strategies, exceeding revenue goals. In addition to her commercial experience, Ms. Spencer-Pike is a dedicated advocate for DE&I, leading the largest US-based Women’s Employee Resource Group (ERG) at Pfizer and Novo Nordisk, both of which were the largest ERGs within the companies. This experience speaks to her commitment to growth and development and fostering inclusive cultures.

Please visit https://nucleusrad.com/#about for more information and to learn more about Nucleus RadioPharma’s partnering opportunities.

About Nucleus RadioPharma

Nucleus RadioPharma is a Contract Development and Manufacturing Organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies. Nucleus RadioPharma's mission is to ensure cancer patients can access potentially lifesaving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new treatment tools.

Contacts

Consort Partners for Nucleus RadioPharma
nucleusradiopharma@consortpartners.com

Nucleus RadioPharma


Release Versions

Contacts

Consort Partners for Nucleus RadioPharma
nucleusradiopharma@consortpartners.com

More News From Nucleus RadioPharma

Nucleus RadioPharma Expands Radiopharmaceutical Research, Development and Manufacturing Capacity, Addressing Nationwide Supply Chain Constraints

ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma today announced the development of two new facilities totaling over 100,000 square feet in Mesa, Arizona and Springhouse, Pennsylvania. These first-of-a-kind facilities will house research, development, and commercial production capabilities under one roof, giving massive time and scale advantage to Nucleus’ partners. This expansion will give the entire radiopharmaceutical industry new capabilities from novel isotope utilization, to broad p...

Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment

ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq: AZN). AstraZeneca joins existing investors from GE Healthcare, Mayo Clinic, Eclipse Ventures, Fox Chase Cancer Center, Echo Global Granger Management Mercy Health, and the University of Missouri as Nucleus expands devel...

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials

CAMBRIDGE, Mass. and ROCHESTER, Minn.--(BUSINESS WIRE)--ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), and Nucleus RadioPharma Inc. (Nucleus), the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced a strategic manufacturing and supply agreement to support ARTBIO’s therapeutic product manufacturing. Under the terms of the agre...
Back to Newsroom